Views & Analysis The cancer challenge: the quest for a cure is only half the ... The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
News NICE rejects Opdivo in head and neck cancer – before it gain... England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
